Myriad Genetics, Inc. (MYGN) AI Stock Analysis

Myriad Genetics, Inc. is a genetic testing and precision medicine company that develops and commercializes advanced molecular diagnostic tests across oncology, women's health, and mental health applications. Its core products include the MyRisk Hereditary Cancer Test, BRACAnalysis CDx for identifying therapies in metastatic cancers with BRCA variants, and the MyChoice CDx companion diagnostic test for ovarian cancer patients. The company also offers RNA expression tests such as Prolaris for prostate cancer and EndoPredict for breast cancer, alongside its Precise Tumor solution. In women's health, it provides the Prequel Prenatal Screen and Foresight Carrier Screen, while GeneSight serves psychotropic mental health applications.

Myriad Genetics delivered a 5-year revenue CAGR of 8.2% from FY2020 to FY2025. Annual revenue grew from $690.6M in FY2021 to a peak of $837.6M in FY2024, before declining 1.6% to $824.5M in FY2025. Gross margin has remained relatively steady, recording 71.4% in FY2021 and 69.9% in both FY2024 and FY2025. Operating margins were negative across all periods, finishing at -8.2% in FY2025. Annual net losses widened from -$27.2M in FY2021 to -$365.9M in FY2025, which included an EPS of -$0.23. For the trailing twelve months ended June 30, 2026, revenue stood at $806.6M, with quarterly revenue falling 10.5% year-over-year.

As of June 30, 2026, Myriad Genetics held $115.2M in cash and short-term investments against total debt of $210.5M, resulting in net debt of $95.3M. Total assets were $638.9M and shareholders' equity stood at $303.9M, with a current ratio of 2.21 and a debt-to-equity ratio of 0.69. In FY2025, the company generated $1.8M in operating cash flow but recorded negative free cash flow of -$25.6M after spending $27.4M on capital expenditures. Over a 5-year period, its share count increased by 18.6%.

At a share price of $3.98, Myriad Genetics carries a market cap of $380.7M and an enterprise value of $478.9M. The stock trades at a forward P/E of 54.1x, higher than the 17.3x forward P/E median of its US-listed Healthcare peers. Its price-to-sales multiple is 0.5x, well below the peer median of 4.1x. Over the past year, the stock fell 50.7%, underperforming the S&P 500 (SPY), which gained 16.8%. Over a 5-year timeframe, the stock has declined 87.5% compared to an 83.0% gain for the benchmark.

Wall Street analysts hold mixed views on Myriad Genetics, with 1 Strong Buy, 5 Holds, 2 Sells, and 1 Strong Sell. The mean price target is $4.11, representing upside of 3.3% from the last close of $3.98. For the fiscal year ending December 31, 2026, analysts anticipate revenue of $777.9M and an EPS of -$0.74. For the following fiscal year, 9 analysts project revenue of $820.5M and an EPS of -$0.59. Over the last four quarters, the company beat EPS estimates 1 time. The next earnings date is November 4, 2026.

This page is an AI-written research summary of Myriad Genetics, Inc. (MYGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MYGN income statement, MYGN balance sheet, MYGN key metrics, MYGN analyst forecast, MYGN chart. See the MYGN stock overview for the latest quote and news.